NCCN Guidelines® Insights

Head and Neck Cancers, Version 2.2013

Featured Updates to the NCCN Guidelines

David G. Pfister, MD; Kie-Kian Ang, MD, PhD; David M. Brizel, MD; Barbara A. Burtness, MD; Paul M. Busse, MD, PhD; Jimmy J. Caudell, MD, PhD; Anthony J. Cmelak, MD; A. Dimitrios Colevas, MD; Frank Dunphy, MD; David W. Eisele, MD; Jill Gilbert, MD; Maura L. Gillison, MD, PhD; Robert I. Haddad, MD; Bruce H. Haughey, MBChB, MS; Wesley L. Hicks Jr, MD; Ying J. Hitchcock, MD; Merrill S. Kies, MD; William M. Lydiatt, MD; Ellie Maghami, MD; Renato Martins, MD, MPH; Thomas McCaffrey, MD, PhD; Bharat B. Mittal, MD; Harlan A. Pinto, MD; John A. Ridge, MD, PhD; Sandeep Samant, MD; David E. Schuller, MD; Jatin P. Shah, MD, PhD; Sharon Spencer, MD; Randal S. Weber, MD; Gregory T. Wolf, MD; Frank Worden, MD; Sue S. Yom, MD, PhD; Nicole R. McMillian, MS; and Miranda Hughes, PhD

Abstract

These NCCN Guidelines Insights focus on nutrition and supportive care for patients with head and neck cancers. This topic was a recent addition to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers. The NCCN Guidelines Insights focus on major updates to the NCCN Guidelines and discuss the new updates in greater detail. The complete version of the NCCN Guidelines for Head and Neck Cancers is available on the NCCN Web site (NCCN.org). (JNCCN 2013;11:917–923)

Please Note

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. The NCCN Guidelines® Insights highlight important changes in the NCCN Guidelines® recommendations from previous versions. Colored markings in the algorithm show changes and the discussion aims to further understanding of these changes by summarizing salient portions of the panel's discussion, including the literature reviewed.

The NCCN Guidelines Insights do not represent the full NCCN Guidelines; further, the National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding the content, use, or application of the NCCN Guidelines and NCCN Guidelines Insights and disclaims any responsibility for their applications or use in any way.

The full and most current version of these NCCN Guidelines are available at NCCN.org.

© National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

Disclosures for the NCCN Head and Neck Cancers Panel

Individual disclosures of potential conflicts of interest for the NCCN Head and Neck Cancers Panel members can be found on page 918.
Disclosure of Affiliations and Significant Relationships: NCCN Head and Neck Cancers Panel

The following authors have no relevant financial interests to disclose: Dr. Busse, Dr. Eisele, Dr. Gillison, Dr. Haddad, Dr. Haughey, Dr. Hicks, Dr. Hitchcock, Dr. Kies, Dr. Lydiatt, Dr. Maghami, Dr. McCaffrey, Dr. Ridge, Dr. Samant, Dr. Shah, Dr. Spencer, Dr. Weber, and Dr. Wolf.

The following authors have disclosed the following relevant financial relationships:

Dr. Ang: Consultant for Eli Lilly and Company.
Dr. Brizel: Advisory board member for Siemens Molecular Imaging.
Dr. Burtness: Advisor for Bristol-Myers Squibb Company. Research funding from Genentech, Inc. and Novartis Pharmaceuticals Corporation. PI for Pfizer Inc. Advisory board member for Amgen Inc.
Dr. Caudell: Consultant for Boehringer Ingelheim GmbH.
Dr. Cmelak: Advisory board member for Amgen Inc.
Dr. Colevas: Clinical research support from Bayer HealthCare; Exelixis Inc.; Genentech, Inc.; and ActoGeniX NV. Research funding from Boehringer Ingelheim GmbH and GlaxoSmithKline. Serves on the Head and Neck Steering Subcommittee for NCI. Site investigator for RTOG and ECOG. Committee member for ECOG.
Dr. Dunphy: PI for Bristol-Myers Squibb Company.
Dr. Gilbert: Serves on the NCI Taskforce Metastatic HNC. Member of ECOG.
Dr. Martins: PI for Bayer HealthCare; Eisai Inc.; Genentech, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc. Clinical research support from Exelixis Inc.
Dr. Mittal: PI for Genentech, Inc.
Dr. Pfister: Clinical trial support from AstraZeneca Pharmaceuticals LP; Exelixis Inc.; Genentech, Inc.; ImClone Systems Incorporated; and Novartis Pharmaceuticals Corporation. Serves on the Data Safety Monitoring Board for Boehringer Ingelheim GmbH.
Dr. Pinto: Site PI for Bristol-Myers Squibb Company. Advisory board member for Eli Lilly and Company.
Dr. Schuller: Cochair Emeritus for NCI.
Dr. Worden: PI for Pfizer Inc. Speakers’ bureau member for Bristol-Myers Squibb Company.
Dr. Yom: PI for Genentech, Inc.

The NCCN Guidelines Staff have no conflicts to disclose.

Supported by educational grants from Eisai, Inc.; Millennium: The Takeda Oncology Company; Teva Pharmaceuticals; Bayer HealthCare Pharmaceuticals Inc.; Celgene Corporation; Endo Pharmaceuticals and HealthTronics; Genentech; and ARIAD Pharmaceuticals, Inc.
Overview

A new section on “Principles of Nutrition” was recently added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers. This new section outlines the management of nutrition and supportive care for patients with head and neck cancers who are prone to weight loss, which can often be severe, as a result of treatment-related toxicity, disease, and health behaviors. Multidisciplinary evaluation is integral to minimizing or decreasing weight loss and should involve a registered dietitian and a speech-language/swallowing therapist.

Before treatment, patients with head and neck cancer are prone to weight loss because they may have difficulty swallowing from pain or obstruction caused by their tumor; patients are also at risk for dehydration. Although multimodality treatment for head and neck cancers is improving outcomes, it can be associated with severe toxicities. Many patients with head and neck cancers will receive radiation-
Principles of Nutrition: Management and Supportive Care

Use of Alternative Routes for Nutrition (NG and PEG Tubes)

- The panel does not recommend prophylactic PEG or NG tube placement in patients with very good PS and without significant pretreatment weight loss, significant airway obstruction, or severe dysphagia. However, these patients will need encouragement to monitor their caloric intake and to assess for changes in body weight during treatment. They also may need temporary tube feeding intervention during and/or after treatment.

- Prophylactic feeding tube placement should be strongly considered for patients with:
  - Severe weight loss prior to treatment, 5% weight loss over prior 1 month, or 10% weight loss over 6 months;
  - Ongoing dehydration or dysphagia, anorexia, or pain interfering with the ability to eat/drink adequately;
  - Significant comorbidities that may be aggravated by poor tolerance of dehydration, lack of caloric intake, or difficulty swallowing necessary medications;
  - Severe aspiration; or mild aspiration in elderly patients or in patients who have compromised cardiopulmonary function;
  - Patients for whom long-term swallowing disorders are likely, including those anticipated to receive large fields of high-dose radiation to the mucosa and adjacent connective tissues. However, consideration of other risk factors for swallowing dysfunction must be taken into account as well.

- To maintain swallowing function during and following treatment (eg, radiation), patients who may have feeding tube placement should be encouraged to intake orally if they can swallow without aspiration or any other compromises. Alterations in swallowing function can occur long after treatment (especially after radiation-based treatment) and should be monitored for the lifetime of the patient.


Based treatments and should receive dietary counseling before treatment. Dysphagia, odynophagia, xerostomia, and dysesthesia are common complications contributing to nutrition problems.1,2,4-10 Surgery can lead to functional impairment regarding chewing and swallowing; chemotherapy is often associated with oral mucositis, nausea, and vomiting.1

Patients with head and neck cancers who have had significant weight loss (>10% ideal body weight) clearly need nutritional evaluation and close monitoring of their weight to prevent further loss.4,11 Therefore, patients should receive nutritional evaluation before and after treatment to assess the need for interventions (eg, enteral support via feeding tubes).12,13 Some patients may require ongoing follow-up if they have chronic nutritional problems. Patients are also at risk for problems with speech. Treatment and/or the progression of their disease may cause deterioration in their ability to speak and/or swallow.6 Patients have reported that swallowing disorders negatively affect their quality of life.9 Evaluation by a speech-language/swallowing specialist can help mitigate potential problems, including rehabilitation of speech in patients after total laryngectomy (eg, esophageal speech, tracheoesophageal puncture).14-16

Progress in radiation and surgical techniques has led to a decrease in the local side effects associated with treatment. For example, intensity-modulated radiation therapy maintains tumor control while decreasing radiation dosing to sites not at risk for cancer involvement, and has been shown to decrease dry mouth after treatment.17 Minimally invasive surgical technology (endoscopes, robots, lasers) facilitates complete removal of primary aerodigestive tract tumors, which can be accessed entirely through the mouth under anesthesia.18-22 When applicable, these surgical techniques result in fewer tracheotomies, shorter postsurgical hospital days, and more rapid resumption of swallowing than conventional surgical approaches.
Head and Neck Cancers, Version 2.2013

Although clinically significant esophageal constriction or stricture is infrequent after treatment with modern radiation techniques, it nonetheless can occur, particularly in patients with primary tumors of the hypopharynx. When esophageal constriction or stricture is present, esophageal dilation can alleviate related dysphagia. In rare cases of complete esophageal obstruction, an anterograde/retrograde approach may be warranted, and referral to a center with this expertise should be strongly considered.

**Feeding Tubes**

The NCCN Head and Neck Panel agrees that reactive feeding tube placement is appropriate in selected patients with head and neck cancers. However, the panel had varying opinions regarding the indications for prophylactic tube placement, although this is commonly performed if high-risk patients will be receiving intense multimodality therapy (eg, concurrent chemoradiation) that is anticipated to cause severe swallowing problems. The NCCN Guidelines provide recommendations for prophylactic tube placement, which should be strongly considered in high-risk patients (eg, those with severe pretreatment weight loss, ongoing dehydration or dysphagia, significant comorbidities, severe aspiration, anticipated posttreatment problems) (see NUTR-A, pages 919 and 920). The NCCN Guidelines do not recommend prophylactic tube placement in lower-risk patients (eg, those without significant pretreatment weight loss, significant aspiration, or severe dysphagia), although these patients must carefully monitor their weight.

Percutaneous endoscopic gastrostomy (PEG) tube feeding is useful for patients with swallowing disorders and those who need prolonged nutritional support. The amount of weight loss is significantly reduced in patients who undergo prophylactic PEG tube placement; however, complications may occur. PEG tubes can lead to infection, aspiration pneumonia, and decreased quality of life. Although patients prefer PEG over nasogastric tubes, they can become dependent on PEG tubes. More advanced disease, altered fractionation, and concurrent chemoradiation are associated with a greater dependence on PEG tubes in patients with oropharyngeal cancer. A recent analysis among patients with swallowing disturbances indicates that mortality rates and pneumonia are similar between the different types of feeding tubes (eg, PEG vs nasogastric tubes); the authors reported that PEG tube feeding seemed to be more effective and as safe as nasogastric tube feeding. However, for patients with head and neck cancer, which is the optimal type of feeding tube is unclear.

**Conclusions**

These NCCN Guidelines Insights focus on nutrition and supportive care for patients with head and neck cancers. Multidisciplinary evaluation is integral to minimizing or decreasing weight loss and speaking and/or swallowing disturbances, and should involve a registered dietitian and a speech-language/swallowing therapist. The NCCN Guidelines provide recommendations for prophylactic feeding tube placement, which should be strongly considered in high-risk patients (eg, those with severe pretreatment weight loss, ongoing dehydration or dysphagia, significant comorbidities, severe aspiration, or anticipated posttreatment problems) (see NUTR-A, pages 919 and 920). The NCCN Guidelines do not recommend prophylactic feeding tube placement in lower-risk patients (eg, those without significant pretreatment weight loss, significant airway obstruction, or severe dysphagia), although these patients must carefully monitor their weight (to view the most recent version of these guidelines, visit the NCCN Web site at NCCN.org).

**References**

Head and Neck Cancers, Version 2.2013


Posttest Questions

1. Prophylactic feeding tube placement should be considered in patients with head and neck cancers who are at high risk for severe weight loss.
   a. True
   b. False

2. Which of the following suggest that patients with head and neck cancer may be at high risk for severe weight loss?
   a. Ongoing dehydration or dysphagia
   b. Treatment with concurrent chemoradiation
   c. Severe aspiration
   d. All of the above
   e. None of the above

3. After total laryngectomy, evaluation by a speech language/swallowing specialist can help patients to rehabilitate their speech.
   a. True
   b. False